See our recent news and announcements below. If you have any questions or for media inquiries, please contact email@example.com for assistance or see specified media contact details within each release.
Waltham, MA, January 10, 2022 –
Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the appointment of Brian Lestini, MD, PhD as Chief Executive Officer. Dr. Lestini joined Pyramid Biosciences in March 2021 as the Chief Medical Officer, overseeing the advancement and expansion of the company’s clinical pipeline of novel targeted medicines. Pyramid Biosciences’ lead program, PBI-200, currently in Phase 1 clinical trials, is an orally-active, CNS penetrant TRK inhibitor targeting a variety of genetically defined cancers, including primary and metastatic brain cancers. [click to read more]